Is proteinuria reduction by angiotensin-converting enzyme inhibition enough to prove its role in renal protection in IgA nephropathy?

Journal of the American Society of Nephrology

Volumn 18, Issue 6, 2007, Pages 1633-1634

  Cattran, Daniel C ^a,b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE; EDITORIAL; ENZYME INHIBITION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 34249894724     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2007040433     Document Type: Editorial

References (16)

1. Barratt J, Feehally J: IgA nephropathy. J Am Soc Nephrol 16: 2088-2097, 2005
2. Wyatt RJ, Kritchevsky SB, Woodford SY, Miller PM, Roy S 3rd, Holland NH, Jackson E, Bishof NA: IgA nephropathy: Long-term prognosis for pediatric patients. J Pediatr 127: 913-919, 1995
3. Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M: A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 10: 101-109, 1999
4. Waldo FB, Wyatt RJ, Kelly DR, Herrera GA, Benfield MR, Kohaut EC: Treatment of IgA nephropathy in children: Efficacy of alternate-day oral prednisone. Pediatr Nephrol 7: 529-532, 1993
5. Welch TR, Fryer C, Shely E, Witte DP, Quinlan M: Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr 121: 474-477, 1992
6. Hogg RJ, Lee J, Nardelli N, Julian BA, Cattran D, Waldo B, Wyatt R, Jennette JC, Sibley R, Hyland K, Fitzgibbons L, Hirschman G, Donadio JVJ, Holub B: Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: Report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 1: 467-474, 2006
7. Coppo R, Peruzzi L, Amore A, Piccoli A, Cohat P, Stone R, Kirschstein M, Linne T; on behalf of the EC Biomed Concerted Action Project BMH4-97-2487 (DG 12-SSMI) and IgACE European Collaborative Group: IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18: 1880-1888, 2007
8. Kanno Y, Okada H, Saruta T, Suzuki H: Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: A 3-year follow-up. Clin Nephrol 54: 360-365, 2000
9. D'Amico G: Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 24: 179-196, 2004
10. Rauta V, Finne P, Fagerudd J, Rosenlof K, Tornroth T, Gronhagen-Riska C: Factors associated with progression of IgA nephropathy are related to renal function: A model for estimating risk of progression in mild disease. Clin Nephrol 58: 85-94, 2002
11. Feehally J: Predicting prognosis in IgA nephropathy. Am J Kidney Dis 38: 881-883, 2001
12. Bartosik LP, Lajoie G, Sugar L, Cattran DC: Predicting progression in IgA nephropathy. Am J Kidney Dis 38: 728-735, 2001
13. Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM: Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant 17: 1197-1203, 2002
14. Cattran DC, Greenwood C, Ritchie S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 23: 247-254, 1994
15. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E: Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 14: 1578-1583, 2003
16. Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC: Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study. Am J Kidney Dis 47: 751-760, 2006